Literature DB >> 21487019

Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Melanie B Laederich1, Catherine R Degnin, Gregory P Lunstrum, Paul Holden, William A Horton.   

Abstract

Fibroblast growth factor receptor 3 (FGFR3) is a key regulator of growth and differentiation, whose aberrant activation causes a number of genetic diseases including achondroplasia and cancer. Hsp90 is a specialized molecular chaperone involved in stabilizing a select set of proteins termed clients. Here, we delineate the relationship of Hsp90 and co-chaperone Cdc37 with FGFR3 and the FGFR family. FGFR3 strongly associates with these chaperone complexes and depends on them for stability and function. Inhibition of Hsp90 function using the geldanamycin analog 17-AAG induces the ubiquitination and degradation of FGFR3 and reduces the signaling capacity of FGFR3. Other FGFRs weakly interact with these chaperones and are differentially influenced by Hsp90 inhibition. The Hsp90-related ubiquitin ligase CHIP is able to interact and destabilize FGFR3. Our results establish FGFR3 as a strong Hsp90 client and suggest that modulating Hsp90 chaperone complexes may beneficially influence the stability and function of FGFR3 in disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487019      PMCID: PMC3103339          DOI: 10.1074/jbc.M110.206151

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.

Authors:  Masahiro Waza; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Chen Sang; Fumiaki Tanaka; Akira Inukai; Manabu Doyu; Gen Sobue
Journal:  Nat Med       Date:  2005-09-11       Impact factor: 53.440

2.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

3.  Hsp90 increases LIM kinase activity by promoting its homo-dimerization.

Authors:  Rong Li; Juliana Soosairajah; Daniel Harari; Ami Citri; John Price; Hooi Ling Ng; Craig J Morton; Michael W Parker; Yosef Yarden; Ora Bernard
Journal:  FASEB J       Date:  2006-04-26       Impact factor: 5.191

4.  Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

Authors:  Isabelle Bernard-Pierrot; Aude Brams; Claire Dunois-Lardé; Aurélie Caillault; Sixtina Gil Diez de Medina; David Cappellen; Gabriel Graff; Jean Paul Thiery; Dominique Chopin; David Ricol; François Radvanyi
Journal:  Carcinogenesis       Date:  2005-12-07       Impact factor: 4.944

5.  Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling.

Authors:  Serena Germano; Davide Barberis; Massimo M Santoro; Lorenza Penengo; Ami Citri; Yosef Yarden; Giovanni Gaudino
Journal:  J Biol Chem       Date:  2006-06-01       Impact factor: 5.157

6.  ErbB2 degradation mediated by the co-chaperone protein CHIP.

Authors:  Pengcheng Zhou; Norvin Fernandes; Ingrid L Dodge; Alagarsamy Lakku Reddi; Navin Rao; Howard Safran; Thomas A DiPetrillo; David E Wazer; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2003-02-06       Impact factor: 5.157

7.  CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.

Authors:  Hiroaki Adachi; Masahiro Waza; Keisuke Tokui; Masahisa Katsuno; Makoto Minamiyama; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

8.  Hsp90 recognizes a common surface on client kinases.

Authors:  Ami Citri; Daniel Harari; Galit Shohat; Parameswaran Ramakrishnan; Judith Gan; Sara Lavi; Miriam Eisenstein; Adi Kimchi; David Wallach; Shmuel Pietrokovski; Yosef Yarden
Journal:  J Biol Chem       Date:  2006-03-21       Impact factor: 5.157

9.  K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.

Authors:  Patricia M-J Lievens; Alessandro Roncador; Elio Liboi
Journal:  J Mol Biol       Date:  2006-02-03       Impact factor: 5.469

10.  Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.

Authors:  Jay Y Cho; Changsheng Guo; Monica Torello; Gregory P Lunstrum; Tomoko Iwata; Chuxia Deng; William A Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

View more
  22 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 2.  HSP90AB1: Helping the good and the bad.

Authors:  Michael Haase; Guido Fitze
Journal:  Gene       Date:  2015-09-07       Impact factor: 3.688

3.  Fibroblast growth factor signaling in myofibroblasts differs from lipofibroblasts during alveolar septation in mice.

Authors:  Stephen E McGowan; Diann M McCoy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-02       Impact factor: 5.464

Review 4.  The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Authors:  Sumera Rizvi; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2016-10

5.  Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.

Authors:  Gayathri Chadalapaka; Indira Jutooru; Stephen Safe
Journal:  Carcinogenesis       Date:  2012-02-14       Impact factor: 4.944

Review 6.  Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Authors:  Mitesh J Borad; Gregory J Gores; Lewis R Roberts
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 7.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

Review 8.  The therapeutic target Hsp90 and cancer hallmarks.

Authors:  Yoshihiko Miyata; Hitoshi Nakamoto; Len Neckers
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.

Authors:  Daniel C Bennett; Jonathan Charest; Katrina Sebolt; Mark Lehrman; Alnawaz Rehemtulla; Joseph N Contessa
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

Review 10.  A place for precision medicine in bladder cancer: targeting the FGFRs.

Authors:  Erica di Martino; Darren C Tomlinson; Sarah V Williams; Margaret A Knowles
Journal:  Future Oncol       Date:  2016-07-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.